***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: PURPOSE Peripheral T-cell lymphomas ( PTCLs ) are a heterogeneous group of malignancies characterized by a poor prognosis . We performed a pilot study to investigate the role of reduced-intensity conditioning ( RIC ) followed by allogeneic stem-cell transplantation in relapsed or refractory PTCLs . PATIENTS AND METHODS We have conducted a phase II trial on 17 patients receiving salvage chemotherapy followed by RIC and allogeneic transplantation of hematopoietic cells .  The RIC regimen consisted of thiotepa , fludarabine , and cyclophosphamide . The acute graft-versus-host disease prophylaxis consisted of cyslosporine and short course methotrexate . RESULTS Patients had a median age of 41 years ( range , 23 to 60 years ) . Two patients were primary chemorefractory , and 15 had relapsed disease ; eight patients ( 47 % ) had a disease relapse after an autologous transplantation . After a median follow-up of 28 months from the day of study entry ( range , 3 to 57 months ) , 14 of 17 patients were alive ( 12 in complete remission , one in partial remission , and one with stable disease ) , two died as a result of progressive disease , and one died as a result of sepsis concomitant to acute graft-versus-host disease . The estimated 3-year overall and progression-free survival rates were 81 % ( 95 % CI , 62 % to 100 % ) and 64 % ( 95 % CI , 39 % to 89 % ) , respectively . The estimated probability of nonrelapse mortality at 2 years was 6 % ( 95 % CI , 1 % to 17 % ) . Donor lymphocyte infusions induced a response in two patients progressing after allografting . CONCLUSION RIC followed by allogeneic stem-cell transplantation is feasible , has a low treatment-related mortality , and seems to be a promising salvage treatment for relapsed PTCL . These findings suggest that the existence of a graft-versus-T-cell lymphoma effect T-cell NHL represent 10 - 15 % of all malignant lymphomas making systematic prospect i ve clinical trials difficult . Therefore , the prognostic significance of the T-cell phenotype has been a matter of controversy in recent years . In a retrospective analysis of 681 patients ( pts ) with NHL accrued from 1992 to 1997 at a single institution , 66 patients with T-cell NHL were identified . According to the REAL classification , histologies were as follows : 28 peripheral T-cell lymphomas ( PTCL ) , 19 large cell anaplastic lymphoma ( LCAL ) , 12 precursor lymphoblastic lymphoma ( Lb ) , and seven AILD . Multiagent anthracycline containing regimens were used as initial therapy in 91 % of cases . T-cell NHL represent 9.8 % of all NHL patients at our institution accrued over a 6-year period . Overall response rate was 76 % , 21 % had progressive disease and 3 % died during first line treatment . Mean overall survival ( OS ) was 8.22 ± 0.94 years . There was a significant difference in OS between the four different histological subgroups ( log rank P = 0.0288 ) . LCAL : mean OS 11.05 ± 1.55 years ( 95 % CI 8.00 - 14.09 ) ; LB : mean OS 7.09 ± 1.40 years ( 95 % CI 4.33 - 9.84 ) ; PTCL : mean 6.62 ± 1.17 years ( 95 % CI 4.33 - 8.90 ) ; AILD : 1.54 ± 0.44 years ( 95 % CI 0.67 - 2.40 ) . OS was also significantly different for patients classified according to the International Prognostic Index (IPI)-score ( log rank P = 0.002 ) . Mean OS for patients with low risk , intermediate low risk , intermediate high risk and high risk was 10.46 ± 1.02 , 6.46 ± 1.79 , 4.50 ± 1.20 and 1.15 ± 0.46 years , respectively . Univariate analysis ( log-rank test ) for prognostic factors also revealed elevated LDH , B-symptoms and extranodal involvement as significant factors for OS . The presence of bulky disease ( > 7.5 cm ) , advanced stage III/IV and bone marrow involvement did not influence OS . In conclusion , it is evident that histological subtype and IPI-score have a strong prognostic impact on OS in pts with T-cell NHL . Thus , the distribution of risk factors in patients with T-cell NHL may be more important for OS than T-cell histology per se PURPOSE Aggressive T-cell lymphomas ( ATCLs ) represent 10 % to 15 % of non-Hodgkin 's lymphomas ( NHLs ) in adults . ATCLs show a worse prognosis than B-cell lymphomas . PATIENTS AND METHODS On behalf of the Société Française de Greffe de Moëlle et de Thérapie Cellulaire , we conducted a retrospective analysis including 77 ATCL patients who underwent allogeneic stem-cell transplantation ( alloSCT ) .  RESULTS The different diagnosis included anaplastic large-cell lymphoma ( ALCL ; n = 27 ) , peripheral T-cell lymphoma not otherwise specified ( PTCL-NOS ; n = 27 ) , angioimmunoblastic T-cell lymphoma ( AITL ; n = 11 ) , hepatosplenic gamma/delta lymphoma ( HSL ; n = 3 ) , T-cell granular lymphocytic leukemia ( T-GLL ; n = 1 ) , nasal natural killer (NK)/T-cell lymphoma ( nasal-NK/L ; n = 3 ) or non-nasal NK/T-cell lymphoma ( non-nasal-NK/L ; n = 2 ) , enteropathy-type T-cell ( n = 1 ) , and human T-lymphotropic virus (HTLV)-1 lymphoma ( n = 2 ) . Fifty-seven patients received a myeloablative conditioning regimen  . Donors were human leukocyte antigen (HLA)-matched in 70 cases and related in 60 cases . Thirty-one patients were in complete remission ( CR ) at the time of alloSCT , whereas 26 were in partial response ( PR ) . Five-year toxicity-related mortality ( TRM ) incidence was 33 % ( 95 % CI , 24 % to 46 % ) . The 5-year overall survival ( OS ) and event-free survival ( EFS ) rates were 57 % ( 95 % CI , 45 % to 68 % ) and 53 % ( 95 % CI , 41 % to 64 % ) , respectively . In multivariate analysis , chemoresistant disease ( stable , refractory , or progressing disease ) at the time of alloSCT and the occurrence of severe grade 3 to 4 acute graft-versus-host disease ( aGVHD ) were the strongest adverse prognostic factors for OS ( P = .03 and .03 , respectively ) . Disease status at transplantation significantly influenced the 5-year EFS ( P = .003 ) , and an HLA-mismatched donor increased TRM ( P = .04 ) . CONCLUSION We conclude that alloSCT is a potentially efficient therapy for NK/T lymphomas and is worth further investigation through prospect i ve clinical trials PURPOSE Systemic peripheral T-cell lymphomas ( PTCLs ) respond poorly to conventional therapy . To evaluate the efficacy of a dose-dense approach consoli date d by up-front high-dose chemotherapy ( HDT ) and autologous stem-cell transplantation ( ASCT ) in PTCL , the Nordic Lymphoma Group ( NLG ) conducted a large prospect i ve phase II study in untreated systemic PTCL . This is the final report , with a 5-year median follow-up , of the NLG-T-01 study . PATIENTS AND METHODS Treatment-naive patients with PTCL age 18 to 67 years ( median , 57 years ) were included . Anaplastic lymphoma kinase ( ALK ) -positive anaplastic large-cell lymphoma ( ALCL ) was excluded . An induction regimen of six cycles of biweekly CHOEP ( cyclophosphamide , doxorubicin , vincristine , etoposide , and prednisone ) was administered ( in patients age > 60 years , etoposide was omitted ) . If in complete or partial remission , patients proceeded to consolidation with HDT/ASCT . RESULTS Of 166 enrolled patients , 160 had histopathologically confirmed PTCL . The majority presented with advanced-stage disease , B symptoms , and elevated serum lactate dehydrogenase .  A total of 115 underwent HDT/ASCT , with 90 in complete remission at 3 months post-transplantation . Early failures occurred in 26 % . Treatment-related mortality was 4 % . At 60.5 months of median follow-up , 83 patients were alive . Consoli date d 5-year overall and progression-free survival ( PFS ) were 51 % ( 95 % CI , 43 % to 59 % ) and 44 % ( 95 % CI , 36 % to 52 % ) , respectively . Best results were obtained in ALK-negative ALCL . CONCLUSION Dose-dense induction followed by HDT/ASCT was well tolerated and led to long-term PFS in 44 % of treatment-naive patients with PTCL . This represents an encouraging outcome , particularly considering the high median age and adverse risk profile of the study population . Therefore , dose-dense induction and HDT/ASCT are a rational up-front strategy in transplantation-eligible patients with PTCL 
    Output:
    
They concluded that ASCT done as part of frontline treatment for PTCL does not improve overall survival .
The results of the meta- analysis reported in this issue of Acta Haematologica do not support the use of ASCT as part of the initial treatment of PTCL .